A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Trial of MORAb-022 in Healthy Subjects and Subjects With Rheumatoid Arthritis.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Trial of MORAb-022 in Healthy Subjects and Subjects With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2016

At a glance

  • Drugs MORAb 022 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Morphotek
  • Most Recent Events

    • 07 Dec 2015 Results published in a Morphotek media release.
    • 12 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 May 2014 Planned End Date changed from 1 May 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top